Association of chemotherapy-induced nausea and vomiting or anorexia with plasma levels of five gastrointestinal peptides in patients receiving chemotherapy.

Ryosuke Tatsuta, Ryota Tanaka, Asami Tashibu, Yosuke Suzuki, Kosuke Suzuki, Tomotaka Shibata, Tadasuke Ando, Toshitaka Shin, Yuhki Sato, Hiroki Itoh
Author Information
  1. Ryosuke Tatsuta: Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan. tatsuta@oita-u.ac.jp.
  2. Ryota Tanaka: Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan.
  3. Asami Tashibu: Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan.
  4. Yosuke Suzuki: Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan.
  5. Kosuke Suzuki: Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Yufu, Oita, Japan.
  6. Tomotaka Shibata: Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Yufu, Oita, Japan.
  7. Tadasuke Ando: Department of Urology, Oita University Faculty of Medicine, Yufu, Oita, Japan.
  8. Toshitaka Shin: Department of Urology, Oita University Faculty of Medicine, Yufu, Oita, Japan.
  9. Yuhki Sato: Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan.
  10. Hiroki Itoh: Department of Clinical Pharmacy, Oita University Hospital, Yufu, Oita, Japan.

Abstract

BACKGROUND: Imbalance between gastrointestinal peptides has been implicated as a cause of chemotherapy-induced nausea and vomiting (CINV) and anorexia in cancer patients. This study comprehensively evaluated the changes in blood levels of five gastrointestinal peptide: substance P, neuropeptide (NPY), motilin, ghrelin and leptin, following chemotherapy, and the relationship between these peptides and CINV or anorexia.
METHODS: This single-center, prospective, observational study recruited 20 patients with esophageal cancer, urothelial cancer, or testiculoma undergoing cisplatin-based chemotherapy. Plasma levels of five gastrointestinal peptides were measured on days 1 (baseline; before administering chemotherapy), 3, 5 and 8 of the chemotherapy session. Anorexia and CINV were defined as visual analog scale scores 25 mm or higher at least once during the observation period.
RESULTS: Plasma NPY and leptin were significantly elevated in the early phase (day 3) of the chemotherapy session, while plasma motilin and substance P were significantly elevated in the late phase (days 5 and 8). Plasma motilin showed significant elevation on days 5 and 8 compared to baseline in CINV group but no significant increase in non-CINV group, and the levels were significantly higher in CINV than in non-CINV group. Plasma leptin peaked significantly on day 3 in both anorexia and non-anorexia groups, and remained significantly higher on day 5 compared to baseline in anorexia group but not in non-anorexia group.
CONCLUSION: CINV is associated with excessive secretion of motilin and anorexia is related to sustained elevation of leptin, suggesting the potential of these peptides as quantitative indicators of CINV and anorexia.

Keywords

References

  1. Qual Life Res. 1992 Oct;1(5):331-40 [PMID: 1299465]
  2. Endocrinol Metab Clin North Am. 2016 Sep;45(3):633-45 [PMID: 27519135]
  3. Cancer Chemother Pharmacol. 2011 Sep;68(3):653-9 [PMID: 21125277]
  4. J Clin Pharmacol. 1993 Aug;33(8):691-7 [PMID: 7691898]
  5. Obes Rev. 2007 Jan;8(1):21-34 [PMID: 17212793]
  6. Gastroenterology. 1972 Mar;62(3):401-4 [PMID: 5011531]
  7. J Am Soc Nephrol. 1998 Jun;9(6):1080-4 [PMID: 9621292]
  8. Int J Clin Oncol. 2021 Jan;26(1):1-17 [PMID: 33161452]
  9. Eur J Clin Nutr. 2004 Feb;58(2):212-8 [PMID: 14749739]
  10. Endocr Rev. 2004 Jun;25(3):426-57 [PMID: 15180951]
  11. Ann N Y Acad Sci. 2006 Nov;1088:23-40 [PMID: 17192554]
  12. J Clin Oncol. 2003 Nov 15;21(22):4112-9 [PMID: 14559886]
  13. Nature. 1999 Dec 9;402(6762):656-60 [PMID: 10604470]
  14. Eur J Clin Nutr. 2007 May;61(5):647-54 [PMID: 17151588]
  15. Nat Rev Gastroenterol Hepatol. 2012 Mar 27;9(5):271-85 [PMID: 22450306]
  16. Eur J Pharmacol. 2013 Sep 5;715(1-3):10-4 [PMID: 23831391]
  17. Nature. 1982 Apr 15;296(5858):659-60 [PMID: 6896083]
  18. Lancet. 1954 Mar 27;266(6813):636-9 [PMID: 13143740]
  19. Eur J Cancer. 2003 May;39(8):1074-80 [PMID: 12736106]
  20. Exp Ther Med. 2019 Apr;17(4):2587-2597 [PMID: 30906450]
  21. Diabet Med. 2002 Aug;19(8):619-27 [PMID: 12147141]
  22. J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):159-167 [PMID: 21475701]
  23. Cancer. 2003 Jun 15;97(12):3090-8 [PMID: 12784346]
  24. Int J Clin Oncol. 2012 Aug;17(4):316-23 [PMID: 21773688]
  25. Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48 [PMID: 10702749]
  26. Regul Pept. 1983 Aug;6(4):363-9 [PMID: 6635258]
  27. Science. 1983 Aug 26;221(4613):877-9 [PMID: 6136091]
  28. Cancer. 2004 May 15;100(10):2261-8 [PMID: 15139073]
  29. Gynecol Oncol. 2016 Mar;140(3):559-64 [PMID: 26748216]
  30. Gastroenterology. 2008 Jun;134(7):2004-13 [PMID: 18439428]
  31. Gastroenterology. 1991 Dec;101(6):1488-96 [PMID: 1955115]
  32. Nature. 2001 Jan 11;409(6817):194-8 [PMID: 11196643]
  33. Dis Esophagus. 2017 Feb 1;30(2):1-7 [PMID: 27001532]

Word Cloud

Created with Highcharts 10.0.0CINVanorexiapeptideschemotherapysignificantlygroupgastrointestinallevelsmotilinleptinPlasma5nauseavomitingcancerpatientsfivedaysbaseline38higherdaychemotherapy-inducedstudysubstancePNPYsessionAnorexiaelevatedphaseplasmasignificantelevationcomparednon-CINVnon-anorexiaBACKGROUND:Imbalanceimplicatedcausecomprehensivelyevaluatedchangesbloodpeptide:neuropeptideghrelinfollowingrelationshipMETHODS:single-centerprospectiveobservationalrecruited20esophagealurothelialtesticulomaundergoingcisplatin-basedmeasured1administeringdefinedvisualanalogscalescores25 mmleastobservationperiodRESULTS:earlylateshowedincreasepeakedgroupsremainedCONCLUSION:associatedexcessivesecretionrelatedsustainedsuggestingpotentialquantitativeindicatorsAssociationreceivingChemotherapy-inducedGastrointestinalLeptinMotilin

Similar Articles

Cited By